43 participants
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-12-31
- Start Date:
- 2026-01-01
- Completion:
- 2027-12-30
Conditions
- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent
Interventions
- DRUG
No Results Yet